A novel mRNA drug, 3’UTRMYC1-18 (UTRxM1-18), has demonstrated notable efficacy in preclinical models of aggressive pancreatic cancer, addressing a disease that is often resistant to conventional treatments.
Positive results for Revolution Medicines Inc.’s phase I studies of its lead candidate, the RAS-blocker daraxonrasib for treating pancreatic ductal adenocarcinoma, prompted the company to say it’s time for a phase III study in the aggressive cancer. Revolution said it plans to begin a global, randomized and registrational trial in first-line metastatic disease sometime in the fourth quarter of 2025.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, primarily due to its dense, desmoplastic and immunosuppressive tumor microenvironment (TME) that hinders the efficacy of immune checkpoint inhibitors such as anti-programmed cell death 1 (PD-1).
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant cancers, with limited therapeutic options and poor survival rates. The development of targeted therapies that disrupt multiple signaling pathways simultaneously could offer new opportunities to improve outcomes in this disease.
Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended. “We’ve concluded that the best way for us to achieve our goals with our rich pipeline is to direct our own global development and commercial strategies and to operationalize these both inside and outside the U.S. through our own organization,” Mark Goldsmith, president and CEO of Revolution Medicines (Revmed), told investors June 24.
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers and needs innovative therapeutic solutions. Patients with PDAC have a 5-year survival rate of about 12%. To address this need, researchers have developed a Drosophila PDAC model harboring the genetic alterations in the KRAS, CDKN2A, TP53 and SMAD4 genes (4-hit model), which accounts for the worst and most aggressive PDAC with lower survival rates.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer characterized by very poor prognosis and resistance to immunotherapy due to an immunosuppressive tumor microenvironment, which includes extensive desmoplasia and a dense stroma.
New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However, investors felt otherwise, as the stock lost about 20% of its value the day the initial results were released.
At the 61st American Society of Clinical Oncology (ASCO) Annual Meeting, multiple companies presented clinical trial data showing their drugs and devices helped patients with pancreatic cancer live longer or improve their ability to respond to treatment.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. The more common BRCA wild-type (wt) subtype is particularly resistant to standard treatments such as gemcitabine and DNA-targeting agents like olaparib.
